---
title: "CRT 2025: Acurate neo2 shows “reassuring” performance in observational study after stuttering IDE trial"
date: "2025-03-15T11:20:34.000Z"
publishedDate: "15 mars 2025"
summary: "Observational data from Sweden’s national registry on coronary and valvular interventions—SWEDEHEART—have shown no difference in rates of mortality, heart failure hospitalisation and stroke among patients receiving the Acurate neo2 (Boston Scientific) when compared to Sapien 3 (Edwards Lifesciences) and Evolut (Medtronic) transcatheter aortic valve implantation (TAVI) systems. The results of the analysis, presented during a [&#8230;] The post CRT 2025: Acurate neo2 shows “reassuring” performance in observational study after stuttering IDE trial appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/crt-2025-acurate-neo2-shows-reassuring-performance-in-observational-study-after-stuttering-ide-trial/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2025-03-15-crt-2025-acurate-neo2-shows-reassuring-performance-in-observational-study-after-stuttering-ide-trial"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2025/03/IMG_3582-scaled.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/crt-2025-acurate-neo2-shows-reassuring-performance-in-observational-study-after-stuttering-ide-trial/"
---

![CRT 2025: Acurate neo2 shows “reassuring” performance in observational study after stuttering IDE trial](https://cardiovascularnews.com/wp-content/uploads/sites/14/2025/03/IMG_3582-scaled.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/crt-2025-acurate-neo2-shows-reassuring-performance-in-observational-study-after-stuttering-ide-trial/*

## L’essentiel

Observational data from Sweden’s national registry on coronary and valvular interventions—SWEDEHEART—have shown no difference in rates of mortality, heart failure hospitalisation and stroke among patients receiving the Acurate neo2 (Boston Scientific) when compared to Sapien 3 (Edwards Lifesciences) and Evolut (Medtronic) transcatheter aortic valve implantation (TAVI) systems. The results of the analysis, presented during a [&#8230;] The post CRT 2025: Acurate neo2 shows “reassuring” performance in observational study after stuttering IDE trial appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/crt-2025-acurate-neo2-shows-reassuring-performance-in-observational-study-after-stuttering-ide-trial/
